What is HC Wainwright’s Estimate for NMRA FY2024 Earnings?

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Investment analysts at HC Wainwright cut their FY2024 earnings estimates for shares of Neumora Therapeutics in a research report issued on Wednesday, November 13th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($1.63) for the year, down from their previous forecast of ($1.37). HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Neumora Therapeutics’ Q4 2024 earnings at ($0.46) EPS, FY2025 earnings at ($1.76) EPS, FY2026 earnings at ($1.77) EPS, FY2027 earnings at ($1.37) EPS and FY2028 earnings at $0.03 EPS.

A number of other equities analysts have also issued reports on NMRA. Royal Bank of Canada reaffirmed an “outperform” rating and set a $29.00 target price on shares of Neumora Therapeutics in a research report on Wednesday, September 4th. Needham & Company LLC restated a “buy” rating and issued a $23.00 price target on shares of Neumora Therapeutics in a research report on Wednesday. Finally, JPMorgan Chase & Co. downgraded shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $18.00 to $15.00 in a report on Tuesday, November 5th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $21.67.

Neumora Therapeutics Stock Down 7.3 %

Shares of NASDAQ NMRA opened at $10.84 on Friday. Neumora Therapeutics has a 12 month low of $8.33 and a 12 month high of $21.00. The company has a market cap of $1.75 billion, a P/E ratio of -5.84 and a beta of 3.92. The business’s 50 day moving average is $13.09 and its two-hundred day moving average is $11.41.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.07). During the same period last year, the business earned ($1.14) earnings per share.

Insider Buying and Selling

In other Neumora Therapeutics news, CFO Joshua Pinto sold 28,496 shares of Neumora Therapeutics stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $11.63, for a total transaction of $331,408.48. Following the sale, the chief financial officer now directly owns 210,469 shares of the company’s stock, valued at approximately $2,447,754.47. The trade was a 11.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Robert A. Lenz sold 30,788 shares of the stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $11.81, for a total value of $363,606.28. Following the completion of the transaction, the insider now directly owns 339,205 shares of the company’s stock, valued at approximately $4,006,011.05. The trade was a 8.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 110,538 shares of company stock valued at $1,390,513 over the last ninety days. 26.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD acquired a new position in Neumora Therapeutics in the first quarter valued at about $10,354,000. State Street Corp boosted its holdings in shares of Neumora Therapeutics by 65.3% in the 3rd quarter. State Street Corp now owns 1,790,707 shares of the company’s stock worth $23,655,000 after acquiring an additional 707,409 shares in the last quarter. Baker BROS. Advisors LP bought a new stake in Neumora Therapeutics during the 1st quarter worth approximately $8,715,000. Callan Capital LLC increased its holdings in Neumora Therapeutics by 222.6% during the 2nd quarter. Callan Capital LLC now owns 661,194 shares of the company’s stock valued at $6,500,000 after purchasing an additional 456,207 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in Neumora Therapeutics by 139.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 698,255 shares of the company’s stock valued at $9,224,000 after purchasing an additional 406,891 shares during the last quarter. 47.65% of the stock is owned by institutional investors.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.